US Stock Market Fluctuation: Regeneron Pharmaceuticals Surges on October 30th as Q3 Exceeds Expectations, Core Drugs Achieve High Growth, and Sanofi Cooperation Strengthens

Regeneron Pharmaceuticals October 30 Surge Explained

Keywords: Q3 Outperformance, Strong Growth of Core Drugs, Sanofi Collaboration

1. On October 30, Regeneron announced its 2026 Q3 financial results, with revenue up 36% year-on-year to $5.1 billion and non-GAAP EPS rising 70% year-on-year to $20.07, both exceeding institutional forecasts.

2. According to the October 30 financial report, global net sales of Dupixent, recorded by Sanofi, increased 35% year-on-year to $6.5 billion; U.S. net sales of EYLEA HD rose 62% year-on-year to $699 million; and global net sales of Libtayo were up 51% year-on-year to $550 million. All three products achieved record net sales.

3. On October 30, the financial report revealed the company is expanding its collaboration with Sanofi, adding several next-generation long-acting immuno-antibodies. The collaboration includes a $1 billion upfront payment to be recognized as collaboration revenue in Q4 2026, with potential future milestone payments that could reach up to $7 billion.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)